• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 29, 2018

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Researchers from MD Anderson Cancer Center have published new findings that argue for a role of the long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) as a metastasis suppressor, rather than promoter, as previous work had suggested.  Read More

Transporter accident: Win fails to materialize in first try, Ultragenyx shields-up

In the company's second program with UX-007 (triheptanoin, or trihep), Ultragenyx Pharmaceutical Inc.'s data are "much more robust" – enough so that the FDA recently said the firm could file an NDA based on phase II findings, spokesperson Danielle Keatley told BioWorld. Read More

Syndax shares sink on phase III PFS miss for entinostat

Shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) fell 17.1 percent to $5.01 Friday on news that adding its HDAC inhibitor, entinostat, to an aromatase inhibitor failed to deliver a statistically significant improvement in the length of time women with hormone receptor-positive, HER2-negative breast cancer lived without worsening of their cancers. The outcome, from the ongoing phase III study E2112, dashed hopes of an early regulatory filing, putting the focus on the trial's other co-primary endpoint, overall survival (OS). Read More

Tiny Anavex thinks big with three-year AD data at CTAD

A day after Biogen Inc. and Eisai Inc. thoroughly confused and mainly disappointed the Alzheimer's disease (AD) field with updated data on BAN-2401, Anavex Life Sciences Corp. took the podium at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) meeting in Barcelona for an oral presentation on lead candidate ANAVEX-2-73. In a starkly different turn from the amyloid beta approach, the oral sigma-1 receptor (S1R) agonist, a tetrahydrofuran derivative, binds to muscarinic acetylcholine 1, seeking to improve measures such as Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), psychomotor function, attention and working memory. Read More

Regenerative med firm Precise Bio launches ophthalmology unit

HAMBURG, Germany – Regenerative medicine startup company Precise Bio Inc. is launching a dedicated ophthalmology business unit to help raise funds and attract partners as it continues to develop bio-printed tissues and organs technology that one day could result in a 3D-printed cornea graft in the human eye. Read More

Sinovac's vaccines business still suffering amid ongoing dispute in the boardroom

HONG KONG – Leading Chinese vaccine maker Sinovac Biotech Ltd. resorted to the Hong Kong courts to fight off an attempted "coup" by a minority shareholder – an attempt that involved presenting allegedly fake documents filed in Hong Kong that suggested top management at Sinovac Biotech's holding company had resigned. Read More

Earnings

Biomarin Pharmaceutical Inc., of San Rafael, Calif., reported that it generated total revenues of $391.7 million for the third quarter, compared to $334.1 million for the quarter ending Sept. 30, 2017, an increase of 17 percent. Net product revenues were $386.3 million, compared to $298.8 million in 2017.  Read More

Financings

Gamida Cell Ltd., of Boston, said it priced its IPO of 6.25 million shares at $8 each, for aggregate gross proceeds of $50 million. The underwriters have been granted a 30-day option to purchase up to 937,500 additional shares at the initial offering price. The company's shares began trading on Nasdaq under the ticker symbol GMDA, closing Friday at $8.44. Read More

Other news to note

Quadrant Biosciences Inc., of Syracuse, N.Y., is collaborating with the Autism Speaks Autism Treatment Network. Quadrant will provide financial support for the Signature Study, testing the antibiotic minocycline on patients with autism spectrum disorder, and will collect salivary RNA data to further elucidate epigenetic factors associated with the disease. Read More

Clinical data for Oct. 26, 2018

Read More

Regulatory actions for Oct. 26, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe